XML 44 R31.htm IDEA: XBRL DOCUMENT v3.7.0.1
Description of Business and Significant Accounting Policies - Additional Information (Detail)
 1 Months Ended 3 Months Ended 6 Months Ended 12 Months Ended
Jun. 29, 2017
USD ($)
Apr. 18, 2017
USD ($)
Mar. 01, 2017
shares
Nov. 09, 2016
USD ($)
Jan. 31, 2017
USD ($)
Jun. 30, 2017
USD ($)
Distributor
shares
Jun. 30, 2017
USD ($)
Distributor
shares
Dec. 31, 2016
USD ($)
Distributor
shares
Jun. 27, 2017
USD ($)
Sep. 30, 2016
shares
Jun. 30, 2016
USD ($)
Dec. 31, 2015
USD ($)
Sep. 23, 2014
Organization, Consolidation and Presentation of Financial Statements Disclosure [Line Items]                          
Net revenue from collaboration           $ 63,000 $ 125,000            
Gain on extinguishment of debt           (830,000) (830,000)            
Accumulated deficit           (2,789,228,000) (2,789,228,000) $ (2,737,565,000)          
Cash and cash equivalents           $ 43,384,000 $ 43,384,000 $ 22,895,000     $ 63,733,000 $ 59,074,000  
Stock split of common stock     0.2                    
Common stock, shares authorized | shares     140,000,000     140,000,000 140,000,000 140,000,000   700,000,000      
Reverse stock split, description             The Company’s board of directors approved a reverse stock split ratio of 1-for-5. On March 1, 2017, the Company filed with the Secretary of State of the State of Delaware a Certificate of Amendment of the Company’s Amended and Restated Certificate of Incorporation (the “Charter Amendment”) to effect the 1-for-5 reverse stock split of the Company’s outstanding common stock (the “Reverse Stock Split”) and to reduce the authorized number of shares of the Company’s common stock from 700,000,000 to 140,000,000 shares. The Company’s common stock began trading on the NASDAQ Global Market on a split-adjusted basis when the market opened on March 3, 2017. As a result, all common stock share amounts included in these condensed consolidated financial statements have been retroactively reduced by a factor of five, and all common stock per share amounts have been increased by a factor of five, with the exception of the Company’s common stock par value.            
Net deferred revenue           $ 2,592,000 $ 2,592,000 $ 3,419,000          
Net revenue - commercial product sales           $ 1,548,000 $ 2,745,000            
Number of wholesale distributors | Distributor           3 3            
Percentage of product shipments to wholesale distributors           93.00% 93.00%            
Deferred revenue from sale of raw insulin             $ 0 $ 1,700,000          
Cash discount as incentive for prompt payment           2.00% 2.00%            
Number of wholesale distributors accounted for gross accounts receivable | Distributor           3 3 3          
Allowance for doubtful accounts           $ 0 $ 0 $ 0          
Percentage of accounts receivable from major wholesale distributors           93.00% 93.00% 95.00%          
Loss on purchase commitments, number of contracts recognized             0 0          
License and Collaboration Agreement with Sanofi                          
Organization, Consolidation and Presentation of Financial Statements Disclosure [Line Items]                          
Gain on extinguishment of debt       $ 500,000                  
Senior notes, effective interest rate                         8.50%
Third party logistics                          
Organization, Consolidation and Presentation of Financial Statements Disclosure [Line Items]                          
Net deferred revenue           $ 1,000,000 $ 1,000,000 $ 800,000          
Insulin Put                          
Organization, Consolidation and Presentation of Financial Statements Disclosure [Line Items]                          
Net revenue from collaboration               10,200,000          
AFREZZA product sales                          
Organization, Consolidation and Presentation of Financial Statements Disclosure [Line Items]                          
Product sales revenue gross to net adjustments           $ 1,100,000 $ 1,500,000            
Product sales revenue gross to net adjustments percentage           41.00% 36.00%            
Minimum | AFREZZA product sales                          
Organization, Consolidation and Presentation of Financial Statements Disclosure [Line Items]                          
Sales return right following product expiration in months             6 months            
Maximum | AFREZZA product sales                          
Organization, Consolidation and Presentation of Financial Statements Disclosure [Line Items]                          
Sales return right following product expiration in months             12 months            
Senior convertible notes due December 31, 2019                          
Organization, Consolidation and Presentation of Financial Statements Disclosure [Line Items]                          
Gain on extinguishment of debt           $ 500,000 $ 500,000            
Senior convertible notes due December 31, 2019 | Less portion of commitment asset                          
Organization, Consolidation and Presentation of Financial Statements Disclosure [Line Items]                          
Gain on extinguishment of debt           300,000 300,000            
Allowance for Sales Returns                          
Organization, Consolidation and Presentation of Financial Statements Disclosure [Line Items]                          
Allowance for returns           200,000 200,000 0          
Principal stockholder | Loan Arrangement                          
Organization, Consolidation and Presentation of Financial Statements Disclosure [Line Items]                          
Available amount of credit facility under covenant restrictions           19,400,000 19,400,000   $ 19,400,000        
Amount available for future borrowings           0 0   $ 30,100,000        
Accrued interest of related party debt           $ 10,700,000 10,700,000 9,300,000          
Sanofi-Aventis Deutschland GmbH | License and Collaboration Agreement with Sanofi                          
Organization, Consolidation and Presentation of Financial Statements Disclosure [Line Items]                          
Net revenue from collaboration             172,000,000            
Sanofi-Aventis Deutschland GmbH | Insulin Put | License and Collaboration Agreement with Sanofi                          
Organization, Consolidation and Presentation of Financial Statements Disclosure [Line Items]                          
Net revenue from collaboration             19,400,000            
Sanofi-Aventis Deutschland GmbH | AFREZZA product sales | License and Collaboration Agreement with Sanofi                          
Organization, Consolidation and Presentation of Financial Statements Disclosure [Line Items]                          
Net revenue from collaboration             $ 17,500,000            
Sanofi-Aventis Deutschland GmbH | Put Option                          
Organization, Consolidation and Presentation of Financial Statements Disclosure [Line Items]                          
Payment for insulin put option         $ 30,600,000     $ 30,600,000          
Aventisub LLC                          
Organization, Consolidation and Presentation of Financial Statements Disclosure [Line Items]                          
Outstanding loan balance forgive       $ 72,000,000                  
Deerfield | Senior convertible notes due December 31, 2019                          
Organization, Consolidation and Presentation of Financial Statements Disclosure [Line Items]                          
Senior notes, effective interest rate           9.75% 9.75%            
Deerfield | Senior convertible notes due December 31, 2019 | Third Amendment [Member]                          
Organization, Consolidation and Presentation of Financial Statements Disclosure [Line Items]                          
Amount available for future borrowings $ 10,000,000                        
Conversion of notes to shares of common Stock, value 5,000,000                        
Deerfield | Senior convertible notes due December 31, 2019 | Less portion of commitment asset                          
Organization, Consolidation and Presentation of Financial Statements Disclosure [Line Items]                          
Senior notes, effective interest rate           8.75% 8.75%            
Cash repayment of senior notes under exchange agreement   $ 4,000,000                      
Conversion of notes to shares of common Stock, value   1,000,000                      
Deerfield | Senior convertible notes due December 31, 2019 | Tranche 1 Notes                          
Organization, Consolidation and Presentation of Financial Statements Disclosure [Line Items]                          
Conversion of notes to shares of common Stock, value   $ 5,000,000                      
Deerfield | Senior convertible notes due December 31, 2019 | Minimum | Less portion of commitment asset                          
Organization, Consolidation and Presentation of Financial Statements Disclosure [Line Items]                          
Available amount of credit facility under covenant restrictions           $ 25,000,000 $ 25,000,000            
Deerfield | Senior convertible notes due December 31, 2019 | Minimum | Less portion of commitment asset | Third Amendment [Member]                          
Organization, Consolidation and Presentation of Financial Statements Disclosure [Line Items]                          
Available amount of credit facility under covenant restrictions $ 10,000,000